APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Medications for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchOral Medications for Multiple Sclerosis Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Oral Medications for Multiple Sclerosis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Medications for Multiple Sclerosis include Sichuan Omnis Pharmaceutical, CGeneTech (Suzhou, China), Qilu Pharmaceutical, Nanjing Healthnice Pharmaceutical, HEC Pharm, Cisen Pharmaceutical, Zydus, Viatris and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Medications for Multiple Sclerosis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Medications for Multiple Sclerosis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Medications for Multiple Sclerosis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Medications for Multiple Sclerosis market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Medications for Multiple Sclerosis Segment by Company

Sichuan Omnis Pharmaceutical

CGeneTech (Suzhou, China)

Qilu Pharmaceutical

Nanjing Healthnice Pharmaceutical

HEC Pharm

Cisen Pharmaceutical

Zydus

Viatris

Teva

Sun Pharmaceuticals

Sanofi

Sandoz

Novartis

Mylan

Merck

Janssen

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Bristol Myers Squibb

Biogen

Banner Life Sciences

Apotex

Alembic

Accord Healthcare

Oral Medications for Multiple Sclerosis Segment by Type

Ozanimod

Ponesimod

Fingolimod

Diroximel Fumarate

Monomethyl Fumarate

Dimethyl Fumarate

Cladribine

Teriflunomide

Siponimod

Oral Medications for Multiple Sclerosis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Oral Medications for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Medications for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Medications for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Medications for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Medications for Multiple Sclerosis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Medications for Multiple Sclerosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Medications for Multiple Sclerosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Medications for Multiple Sclerosis Industry Trends Table 2. Oral Medications for Multiple Sclerosis Industry Drivers Table 3. Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges Table 4. Oral Medications for Multiple Sclerosis Industry Restraints Table 5. Global Oral Medications for Multiple Sclerosis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Medications for Multiple Sclerosis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers Table 9. Global Oral Medications for Multiple Sclerosis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Medications for Multiple Sclerosis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Medications for Multiple Sclerosis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Medications for Multiple Sclerosis Manufacturers, Product Type & Application Table 13. Global Oral Medications for Multiple Sclerosis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Medications for Multiple Sclerosis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ozanimod Table 17. Major Manufacturers of Ponesimod Table 18. Major Manufacturers of Fingolimod Table 19. Major Manufacturers of Diroximel Fumarate Table 20. Major Manufacturers of Monomethyl Fumarate Table 21. Major Manufacturers of Dimethyl Fumarate Table 22. Major Manufacturers of Cladribine Table 23. Major Manufacturers of Teriflunomide Table 24. Major Manufacturers of Siponimod Table 25. Global Oral Medications for Multiple Sclerosis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 27. Global Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 28. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2026) Table 29. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2027-2032) Table 30. Global Oral Medications for Multiple Sclerosis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 31. Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (K Units) Table 32. Global Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (K Units) Table 33. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2026) Table 34. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2027-2032) Table 35. Major Manufacturers of Hospital and Clinic Table 36. Major Manufacturers of Retail Pharmacies Table 37. Major Manufacturers of Other Table 38. Global Oral Medications for Multiple Sclerosis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 40. Global Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 41. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2026) Table 42. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2027-2032) Table 43. Global Oral Medications for Multiple Sclerosis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 44. Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (K Units) Table 45. Global Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (K Units) Table 46. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2026) Table 47. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2027-2032) Table 48. Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (K Units) Table 50. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2026) Table 51. Global Oral Medications for Multiple Sclerosis Sales Forecasted by Region (2027-2032) & (K Units) Table 52. Global Oral Medications for Multiple Sclerosis Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 55. North America Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 56. Europe Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 58. Europe Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 59. Asia Pacific Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 61. Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 62. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 63. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 64. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 65. Global Oral Medications for Multiple Sclerosis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Oral Medications for Multiple Sclerosis Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Oral Medications for Multiple Sclerosis Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2026) Table 69. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2027-2032) Table 70. Sichuan Omnis Pharmaceutical Company Information Table 71. Sichuan Omnis Pharmaceutical Business Overview Table 72. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 74. Sichuan Omnis Pharmaceutical Recent Development Table 75. CGeneTech (Suzhou, China) Company Information Table 76. CGeneTech (Suzhou, China) Business Overview Table 77. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio Table 79. CGeneTech (Suzhou, China) Recent Development Table 80. Qilu Pharmaceutical Company Information Table 81. Qilu Pharmaceutical Business Overview Table 82. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 84. Qilu Pharmaceutical Recent Development Table 85. Nanjing Healthnice Pharmaceutical Company Information Table 86. Nanjing Healthnice Pharmaceutical Business Overview Table 87. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 89. Nanjing Healthnice Pharmaceutical Recent Development Table 90. HEC Pharm Company Information Table 91. HEC Pharm Business Overview Table 92. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio Table 94. HEC Pharm Recent Development Table 95. Cisen Pharmaceutical Company Information Table 96. Cisen Pharmaceutical Business Overview Table 97. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 99. Cisen Pharmaceutical Recent Development Table 100. Zydus Company Information Table 101. Zydus Business Overview Table 102. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Zydus Oral Medications for Multiple Sclerosis Product Portfolio Table 104. Zydus Recent Development Table 105. Viatris Company Information Table 106. Viatris Business Overview Table 107. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Viatris Oral Medications for Multiple Sclerosis Product Portfolio Table 109. Viatris Recent Development Table 110. Teva Company Information Table 111. Teva Business Overview Table 112. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Teva Oral Medications for Multiple Sclerosis Product Portfolio Table 114. Teva Recent Development Table 115. Sun Pharmaceuticals Company Information Table 116. Sun Pharmaceuticals Business Overview Table 117. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 119. Sun Pharmaceuticals Recent Development Table 120. Sanofi Company Information Table 121. Sanofi Business Overview Table 122. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sanofi Oral Medications for Multiple Sclerosis Product Portfolio Table 124. Sanofi Recent Development Table 125. Sandoz Company Information Table 126. Sandoz Business Overview Table 127. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Sandoz Oral Medications for Multiple Sclerosis Product Portfolio Table 129. Sandoz Recent Development Table 130. Novartis Company Information Table 131. Novartis Business Overview Table 132. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Novartis Oral Medications for Multiple Sclerosis Product Portfolio Table 134. Novartis Recent Development Table 135. Mylan Company Information Table 136. Mylan Business Overview Table 137. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Mylan Oral Medications for Multiple Sclerosis Product Portfolio Table 139. Mylan Recent Development Table 140. Merck Company Information Table 141. Merck Business Overview Table 142. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Merck Oral Medications for Multiple Sclerosis Product Portfolio Table 144. Merck Recent Development Table 145. Janssen Company Information Table 146. Janssen Business Overview Table 147. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Janssen Oral Medications for Multiple Sclerosis Product Portfolio Table 149. Janssen Recent Development Table 150. Glenmark Pharmaceuticals Company Information Table 151. Glenmark Pharmaceuticals Business Overview Table 152. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 154. Glenmark Pharmaceuticals Recent Development Table 155. Dr. Reddy's Laboratories Company Information Table 156. Dr. Reddy's Laboratories Business Overview Table 157. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio Table 159. Dr. Reddy's Laboratories Recent Development Table 160. Bristol Myers Squibb Company Information Table 161. Bristol Myers Squibb Business Overview Table 162. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio Table 164. Bristol Myers Squibb Recent Development Table 165. Biogen Company Information Table 166. Biogen Business Overview Table 167. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Biogen Oral Medications for Multiple Sclerosis Product Portfolio Table 169. Biogen Recent Development Table 170. Banner Life Sciences Company Information Table 171. Banner Life Sciences Business Overview Table 172. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio Table 174. Banner Life Sciences Recent Development Table 175. Apotex Company Information Table 176. Apotex Business Overview Table 177. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Apotex Oral Medications for Multiple Sclerosis Product Portfolio Table 179. Apotex Recent Development Table 180. Alembic Company Information Table 181. Alembic Business Overview Table 182. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Alembic Oral Medications for Multiple Sclerosis Product Portfolio Table 184. Alembic Recent Development Table 185. Accord Healthcare Company Information Table 186. Accord Healthcare Business Overview Table 187. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio Table 189. Accord Healthcare Recent Development Table 190. Key Raw Materials Table 191. Raw Materials Key Suppliers Table 192. Oral Medications for Multiple Sclerosis Distributors List Table 193. Oral Medications for Multiple Sclerosis Customers List Table 194. Research Programs/Design for This Report Table 195. Authors List of This Report Table 196. Secondary Sources Table 197. Primary Sources List of Figures Figure 1. Oral Medications for Multiple Sclerosis Product Image Figure 2. Global Oral Medications for Multiple Sclerosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Medications for Multiple Sclerosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Medications for Multiple Sclerosis Sales (2021-2032) & (K Units) Figure 5. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Medications for Multiple Sclerosis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ozanimod Image Figure 9. Ponesimod Image Figure 10. Fingolimod Image Figure 11. Diroximel Fumarate Image Figure 12. Monomethyl Fumarate Image Figure 13. Dimethyl Fumarate Image Figure 14. Cladribine Image Figure 15. Teriflunomide Image Figure 16. Siponimod Image Figure 17. Global Oral Medications for Multiple Sclerosis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Oral Medications for Multiple Sclerosis Sales Market Share 2021 VS 2025 VS 2032 Figure 19. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032) Figure 20. Global Oral Medications for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Oral Medications for Multiple Sclerosis Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032) Figure 23. Hospital and Clinic Image Figure 24. Retail Pharmacies Image Figure 25. Other Image Figure 26. Global Oral Medications for Multiple Sclerosis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Oral Medications for Multiple Sclerosis Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2032) Figure 29. Global Oral Medications for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Oral Medications for Multiple Sclerosis Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2032) Figure 32. North America Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. North America Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 34. U.S. Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Canada Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Mexico Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Europe Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 39. Germany Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. France Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. U.K. Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Italy Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Netherlands Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Asia Pacific Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 46. China Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Japan Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Korea Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Southeast Asia Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 50. India Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Australia Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2032) Figure 54. Brazil Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. South Africa Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Saudi Arabia Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Turkey Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Argentina Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 59. UAE Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Egypt Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Chile Oral Medications for Multiple Sclerosis Sales and Growth Rate (2021-2032) & (K Units) Figure 62. Global Oral Medications for Multiple Sclerosis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Figure 65. North America Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Figure 67. Europe Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Oral Medications for Multiple Sclerosis Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Oral Medications for Multiple Sclerosis Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Ozanimod
  • Ponesimod
  • Fingolimod
  • Diroximel Fumarate
  • Monomethyl Fumarate
  • Dimethyl Fumarate
  • Cladribine
  • Teriflunomide
  • Siponimod
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Sichuan Omnis Pharmaceutical
  • CGeneTech (Suzhou, China)
  • Qilu Pharmaceutical
  • Nanjing Healthnice Pharmaceutical
  • HEC Pharm
  • Cisen Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Sun Pharmaceuticals
  • Sanofi
  • Sandoz
  • Novartis
  • Mylan
  • Merck
  • Janssen
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Biogen
  • Banner Life Sciences
  • Apotex
  • Alembic
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Medications for Multiple Sclerosis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Medications for Multiple Sclerosis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Medications for Multiple Sclerosis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Medications for Multiple Sclerosis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Medications for Multiple Sclerosis Market Dynamics
  1. 2.1 Oral Medications for Multiple Sclerosis Industry Trends
  2. 2.2 Oral Medications for Multiple Sclerosis Industry Drivers
  3. 2.3 Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Oral Medications for Multiple Sclerosis Industry Restraints
3 Oral Medications for Multiple Sclerosis Market by Manufacturers
  1. 3.1 Global Oral Medications for Multiple Sclerosis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Medications for Multiple Sclerosis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Medications for Multiple Sclerosis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Medications for Multiple Sclerosis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Medications for Multiple Sclerosis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Medications for Multiple Sclerosis Manufacturers, Product Type & Application
  7. 3.7 Global Oral Medications for Multiple Sclerosis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Medications for Multiple Sclerosis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Medications for Multiple Sclerosis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Medications for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
4 Oral Medications for Multiple Sclerosis Market by Type
  1. 4.1 Oral Medications for Multiple Sclerosis Type Introduction
  2. 4.1.1 Ozanimod
  3. 4.1.2 Ponesimod
  4. 4.1.3 Fingolimod
  5. 4.1.4 Diroximel Fumarate
  6. 4.1.5 Monomethyl Fumarate
  7. 4.1.6 Dimethyl Fumarate
  8. 4.1.7 Cladribine
  9. 4.1.8 Teriflunomide
  10. 4.1.9 Siponimod
  11. 4.2 Global Oral Medications for Multiple Sclerosis Sales by Type
  12. 4.2.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  14. 4.2.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032)
  15. 4.3 Global Oral Medications for Multiple Sclerosis Revenue by Type
  16. 4.3.1 Global Oral Medications for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  18. 4.3.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032)
5 Oral Medications for Multiple Sclerosis Market by Application
  1. 5.1 Oral Medications for Multiple Sclerosis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Oral Medications for Multiple Sclerosis Sales by Application
  6. 5.2.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 5.2.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2032)
  9. 5.3 Global Oral Medications for Multiple Sclerosis Revenue by Application
  10. 5.3.1 Global Oral Medications for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  12. 5.3.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2032)
6 Global Oral Medications for Multiple Sclerosis Sales by Region
  1. 6.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Medications for Multiple Sclerosis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Medications for Multiple Sclerosis Revenue by Region
  1. 7.1 Global Oral Medications for Multiple Sclerosis Revenue by Region
  2. 7.1.1 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Medications for Multiple Sclerosis Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Medications for Multiple Sclerosis Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Medications for Multiple Sclerosis Revenue (2021-2032)
  8. 7.2.2 North America Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Medications for Multiple Sclerosis Revenue (2021-2032)
  11. 7.3.2 Europe Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Medications for Multiple Sclerosis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Medications for Multiple Sclerosis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Medications for Multiple Sclerosis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sichuan Omnis Pharmaceutical
  2. 8.1.1 Sichuan Omnis Pharmaceutical Company Information
  3. 8.1.2 Sichuan Omnis Pharmaceutical Business Overview
  4. 8.1.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  6. 8.1.5 Sichuan Omnis Pharmaceutical Recent Developments
  7. 8.2 CGeneTech (Suzhou, China)
  8. 8.2.1 CGeneTech (Suzhou, China) Company Information
  9. 8.2.2 CGeneTech (Suzhou, China) Business Overview
  10. 8.2.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
  12. 8.2.5 CGeneTech (Suzhou, China) Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Nanjing Healthnice Pharmaceutical
  20. 8.4.1 Nanjing Healthnice Pharmaceutical Company Information
  21. 8.4.2 Nanjing Healthnice Pharmaceutical Business Overview
  22. 8.4.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  24. 8.4.5 Nanjing Healthnice Pharmaceutical Recent Developments
  25. 8.5 HEC Pharm
  26. 8.5.1 HEC Pharm Company Information
  27. 8.5.2 HEC Pharm Business Overview
  28. 8.5.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
  30. 8.5.5 HEC Pharm Recent Developments
  31. 8.6 Cisen Pharmaceutical
  32. 8.6.1 Cisen Pharmaceutical Company Information
  33. 8.6.2 Cisen Pharmaceutical Business Overview
  34. 8.6.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  36. 8.6.5 Cisen Pharmaceutical Recent Developments
  37. 8.7 Zydus
  38. 8.7.1 Zydus Company Information
  39. 8.7.2 Zydus Business Overview
  40. 8.7.3 Zydus Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
  42. 8.7.5 Zydus Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
  54. 8.9.5 Teva Recent Developments
  55. 8.10 Sun Pharmaceuticals
  56. 8.10.1 Sun Pharmaceuticals Company Information
  57. 8.10.2 Sun Pharmaceuticals Business Overview
  58. 8.10.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  60. 8.10.5 Sun Pharmaceuticals Recent Developments
  61. 8.11 Sanofi
  62. 8.11.1 Sanofi Company Information
  63. 8.11.2 Sanofi Business Overview
  64. 8.11.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
  66. 8.11.5 Sanofi Recent Developments
  67. 8.12 Sandoz
  68. 8.12.1 Sandoz Company Information
  69. 8.12.2 Sandoz Business Overview
  70. 8.12.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
  72. 8.12.5 Sandoz Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
  78. 8.13.5 Novartis Recent Developments
  79. 8.14 Mylan
  80. 8.14.1 Mylan Company Information
  81. 8.14.2 Mylan Business Overview
  82. 8.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
  84. 8.14.5 Mylan Recent Developments
  85. 8.15 Merck
  86. 8.15.1 Merck Company Information
  87. 8.15.2 Merck Business Overview
  88. 8.15.3 Merck Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
  90. 8.15.5 Merck Recent Developments
  91. 8.16 Janssen
  92. 8.16.1 Janssen Company Information
  93. 8.16.2 Janssen Business Overview
  94. 8.16.3 Janssen Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
  96. 8.16.5 Janssen Recent Developments
  97. 8.17 Glenmark Pharmaceuticals
  98. 8.17.1 Glenmark Pharmaceuticals Company Information
  99. 8.17.2 Glenmark Pharmaceuticals Business Overview
  100. 8.17.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  102. 8.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 8.18 Dr. Reddy's Laboratories
  104. 8.18.1 Dr. Reddy's Laboratories Company Information
  105. 8.18.2 Dr. Reddy's Laboratories Business Overview
  106. 8.18.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
  108. 8.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 8.19 Bristol Myers Squibb
  110. 8.19.1 Bristol Myers Squibb Company Information
  111. 8.19.2 Bristol Myers Squibb Business Overview
  112. 8.19.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
  114. 8.19.5 Bristol Myers Squibb Recent Developments
  115. 8.20 Biogen
  116. 8.20.1 Biogen Company Information
  117. 8.20.2 Biogen Business Overview
  118. 8.20.3 Biogen Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
  120. 8.20.5 Biogen Recent Developments
  121. 8.21 Banner Life Sciences
  122. 8.21.1 Banner Life Sciences Company Information
  123. 8.21.2 Banner Life Sciences Business Overview
  124. 8.21.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
  126. 8.21.5 Banner Life Sciences Recent Developments
  127. 8.22 Apotex
  128. 8.22.1 Apotex Company Information
  129. 8.22.2 Apotex Business Overview
  130. 8.22.3 Apotex Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
  132. 8.22.5 Apotex Recent Developments
  133. 8.23 Alembic
  134. 8.23.1 Alembic Company Information
  135. 8.23.2 Alembic Business Overview
  136. 8.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
  138. 8.23.5 Alembic Recent Developments
  139. 8.24 Accord Healthcare
  140. 8.24.1 Accord Healthcare Company Information
  141. 8.24.2 Accord Healthcare Business Overview
  142. 8.24.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
  144. 8.24.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Medications for Multiple Sclerosis Value Chain Analysis
  2. 9.1.1 Oral Medications for Multiple Sclerosis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Medications for Multiple Sclerosis Production Mode & Process
  6. 9.2 Oral Medications for Multiple Sclerosis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Medications for Multiple Sclerosis Distributors
  9. 9.2.3 Oral Medications for Multiple Sclerosis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst